VAP-1 Antibody (D-1): sc-374561

VAP-1 Antibody (D-1) is a mouse monoclonal IgG1 antibody that detects VAP-1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). VAP-1, or vascular adhesion protein-1, plays a crucial role in the immune response by facilitating lymphocyte adhesion to vascular endothelium, which is essential for immune cell migration from bloodstream to lymphoid tissues and inflammation sites. VAP-1 is a type II transmembrane sialoglycoprotein characterized by a single transmembrane domain and multiple N- and O-glycosylation sites within its extracellular domain, which are vital for function. VAP-1 predominantly exists as a homodimer in vivo and serves dual functions as both a monoamine oxidase and an adhesion molecule. Proper glycosylation of VAP-1 enables lymphocyte adhesion under inflammatory conditions, thereby acting as an adhesion receptor supporting lymphocyte recirculation. While VAP-1 is expressed in various smooth muscle cells, VAP-1 does not facilitate lymphocyte binding in these cells but is involved in primary amine deamination. Soluble forms of VAP-1 are present in circulation, with elevated levels observed in patients suffering from inflammatory liver diseases, highlighting VAP-1′s potential as a biomarker for inflammation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VAP-1 Antibody (D-1) References:

1. A peptide inhibitor of vascular adhesion protein-1 (VAP-1) blocks leukocyte-endothelium interactions under shear stress.  |  Yegutkin, GG., et al. 2004. Eur J Immunol. 34: 2276-85. PMID: 15259025
2. VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: effects of statins.  |  Anger, T., et al. 2007. Exp Mol Pathol. 83: 435-42. PMID: 17490641
3. Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke.  |  Hernandez-Guillamon, M., et al. 2010. Stroke. 41: 1528-35. PMID: 20538694
4. Homing-associated molecules CD73 and VAP-1 as targets to prevent harmful inflammations and cancer spread.  |  Salmi, M. and Jalkanen, S. 2011. FEBS Lett. 585: 1543-50. PMID: 21515268
5. Reaction of vascular adhesion protein-1 (VAP-1) with primary amines: mechanistic insights from isotope effects and quantitative structure-activity relationships.  |  Heuts, DP., et al. 2011. J Biol Chem. 286: 29584-93. PMID: 21737458
6. Vascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseases.  |  Solé, M. and Unzeta, M. 2011. Biol Cell. 103: 543-57. PMID: 21819380
7. Mini-PEG spacering of VAP-1-targeting 68Ga-DOTAVAP-P1 peptide improves PET imaging of inflammation.  |  Autio, A., et al. 2011. EJNMMI Res. 1: 10. PMID: 22214508
8. Assessment of the Relationship Between Serum Vascular Adhesion Protein-1 (VAP-1) and Severity of Calcific Aortic Valve Stenosis.  |  Altug Cakmak, H., et al. 2015. J Heart Valve Dis. 24: 699-706. PMID: 27997774
9. Different forms of human vascular adhesion protein-1 (VAP-1) in blood vessels in vivo and in cultured endothelial cells: implications for lymphocyte-endothelial cell adhesion models.  |  Salmi, M. and Jalkanen, S. 1995. Eur J Immunol. 25: 2803-12. PMID: 7589075
10. Lymphocyte binding to vascular endothelium in inflamed skin revisited: a central role for vascular adhesion protein-1 (VAP-1).  |  Arvilommi, AM., et al. 1996. Eur J Immunol. 26: 825-33. PMID: 8625974

The preferred VAP-1 antibody is VAP-1 Antibody (A-8): sc-166713.